- Home
- VERA vs AKRO Comparison
VERA vs AKRO Comparison
Compare VERA & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERA
- AKRO
- Stock Information
- Founded
- VERA 2016
- AKRO 2017
- Country
- VERA United States
- AKRO United States
- Employees
- VERA N/A
- AKRO N/A
- Industry
- VERA Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- VERA Health Care
- AKRO Health Care
- Exchange
- VERA Nasdaq
- AKRO Nasdaq
- Market Cap
- VERA 2.5B
- AKRO 2.1B
- IPO Year
- VERA 2021
- AKRO 2019
- Fundamental
- Price
- VERA $42.01
- AKRO $31.59
- Analyst Decision
- VERA Strong Buy
- AKRO Strong Buy
- Analyst Count
- VERA 9
- AKRO 7
- Target Price
- VERA $53.56
- AKRO $43.20
- AVG Volume (30 Days)
- VERA 683.6K
- AKRO 441.5K
- Earning Date
- VERA 11-07-2024
- AKRO 11-11-2024
- Dividend Yield
- VERA N/A
- AKRO N/A
- EPS Growth
- VERA N/A
- AKRO N/A
- EPS
- VERA N/A
- AKRO N/A
- Revenue
- VERA N/A
- AKRO N/A
- Revenue This Year
- VERA N/A
- AKRO N/A
- Revenue Next Year
- VERA N/A
- AKRO N/A
- P/E Ratio
- VERA N/A
- AKRO N/A
- Revenue Growth
- VERA N/A
- AKRO N/A
- 52 Week Low
- VERA $9.68
- AKRO $11.36
- 52 Week High
- VERA $50.78
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- VERA 52.57
- AKRO 66.34
- Support Level
- VERA $39.22
- AKRO $29.34
- Resistance Level
- VERA $50.00
- AKRO $32.15
- Average True Range (ATR)
- VERA 2.41
- AKRO 1.26
- MACD
- VERA 0.24
- AKRO 0.10
- Stochastic Oscillator
- VERA 28.53
- AKRO 99.74
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.